Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes

Sivaprasad, Sobha, Ghanchi, Faruque, Kelly, Simon P., Kotagiri, Ajay, Talks, James, Scanlon, Peter H ORCID: 0000-0001-8513-710X, McGoey, Hellen, Nolan, Andrew, Saddiq, Moneeb and Napier, Jackie (2023) Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes. Eye, 37. pp. 2753-2760. doi:10.1038/s41433-023-02409-y

Preview	Text (Final published version) 12528 Sivaprasad et al (2023) Evaluation of care with intravitreal aflibercept.pdf - Published Version Available under License Creative Commons Attribution 4.0. Download (1MB) | Preview
Preview	Text (Online first version) Sivaprasad & Scanlon (2023) Evaluation of care with intravitreal aflibercept treatment.pdf - Published Version Available under License Creative Commons Attribution 4.0. Download (1MB) | Preview

Abstract

Background/ objectives: DRAKO (NCT02850263) was a 24-month, prospective, observational, multi-centre cohort study that enrolled patients diagnosed with diabetic macular oedema (DMO) including central involvement. The study aimed to evaluate standard of care intravitreal aflibercept (IVT-AFL) treatment in the UK. This analysis describes the 12-month outcomes for patients with prior anti-vascular endothelial growth factor (VEGF) treatment for DMO other than IVT-AFL (C2), and 2-year outcomes for both anti-VEGF treatment-naïve patients (C1) and C2 patients. Methods: Study eyes were treated with IVT-AFL as per local standard of care. Mean changes in best-corrected visual acuity (BCVA) in ETDRS letters and central subfield thickness (CST) were stratified by baseline factors. Changes in diabetic retinopathy assessments, glycated haemoglobin A1c levels and vision-related quality of life (QoL) were evaluated alongside numbers of injections administered and safety outcomes. Results: For C1, mean (SD) changes from baseline in BCVA of +0.7 (12.7) letters and CST of -123.3 (104.3) µm were observed at Month 24. For C2, mean (SD) changes from baseline for BCVA of + 0.2 (10.2) letters and -0.3 (13.0) letters, and CST of -79.1 (137.6) µm and -91.6 (132.9) µm, were observed at 12 and 24 months, respectively. In Year 2, C1 and C2 patients received a mean of 3.7 and 4.3 injections, respectively. Conclusions: Year 2 results indicate that IVT-AFL is an effective treatment for DMO in real-world UK clinical practice, despite relatively low injection numbers. The high baseline visual acuity and QoL scores were maintained and there was further improvement in anatomical outcomes.

Item Type:	Article
Article Type:	Article
Uncontrolled Keywords:	Diabetic macular oedema; Intravitreal aflibercept treatment
Subjects:	R Medicine > RA Public aspects of medicine > RA645.A-Z Individual diseases or groups of diseases, A-Z > RA645.D54 Diabetes R Medicine > RE Ophthalmology
Divisions:	Schools and Research Institutes > School of Health and Social Care
Research Priority Areas:	Health, Life Sciences, Sport and Wellbeing
Depositing User:	Susan Turner
Date Deposited:	23 Mar 2023 12:22
Last Modified:	14 Sep 2023 10:45
URI:	https://eprints.glos.ac.uk/id/eprint/12528

University Staff: Request a correction | Repository Editors: Update this record